Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in <i>Enterobacterales</i>-Reference-Cited by-同舟云学术

Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Enterobacterales

Published:2023-05-17 Issue:5 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sadek Mustafa¹²^ORCID,Bosch Duran Juan¹,Poirel Laurent¹³^ORCID,Nordmann Patrice¹³⁴^ORCID

Affiliation:

1. Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

2. Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt

3. Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland

4. Institute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland

Abstract

The in vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam, and cefiderocol was evaluated against both clinical and isogenic enterobacterial isolates producing carbapenemases of the SME, NmcA, FRI, and IMI types. Ceftazidime-avibactam and meropenem-vaborbactam showed the highest activity against all tested isolates; imipenem-relebactam showed only moderate activity.

Funder

University of Fribourg

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00078-23

Reference22 articles.

1. Centers for Disease Control. 2013. Antibiotic resistance threats in the United States 2013. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.

2. Global Spread of Carbapenemase-producingEnterobacteriaceae

3. Genetic and Biochemical Characterization of FRI-1, a Carbapenem-Hydrolyzing Class A β-Lactamase from Enterobacter cloacae

4. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria

5. Carbapenemases: molecular diversity and clinical consequences

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergence of a novel FRI-type carbapenemase; blaFRI-12 in Enterobacter asburiae located on an IncR plasmid;European Journal of Clinical Microbiology & Infectious Diseases;2024-07-24

2. Emergence of a novel FRI-type carbapenemase; blaFRI-12 in Enterobacter asburiae located on an IncR plasmid;2024-07-22

3. Improved Blue Carba test and Carba NP test for detection and classification of major Class A and B carbapenemases, including dual producers, among Gram-negative bacilli;Journal of Clinical Microbiology;2024-07-16

4. Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020–2022;International Journal of Antimicrobial Agents;2024-05

5. Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa;Clinical Infectious Diseases;2024-02-02